1779 related articles for article (PubMed ID: 18075247)
21. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
[TBL] [Abstract][Full Text] [Related]
22. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?
Wu T; Willett WC; Rifai N; Shai I; Manson JE; Rimm EB
J Am Coll Cardiol; 2006 Sep; 48(5):973-9. PubMed ID: 16949489
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates.
Gillett MP; Obineche EN; Khan ST; Abdulle AM
Saudi Med J; 2004 Nov; 25(11):1611-6. PubMed ID: 15573187
[TBL] [Abstract][Full Text] [Related]
24. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients.
Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L
J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040
[TBL] [Abstract][Full Text] [Related]
25. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
[TBL] [Abstract][Full Text] [Related]
26. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
Samouilidou EC; Grapsa E
Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
[TBL] [Abstract][Full Text] [Related]
27. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
[TBL] [Abstract][Full Text] [Related]
28. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
[TBL] [Abstract][Full Text] [Related]
29. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
30. Malnutrition, inflammation, and lipids in a cohort of dialysis patients.
Bowden RG; Wilson RL
Postgrad Med; 2010 May; 122(3):196-202. PubMed ID: 20463430
[TBL] [Abstract][Full Text] [Related]
31. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
[TBL] [Abstract][Full Text] [Related]
32. Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure?
Healy H; Reith D; Morgan C; Clague A; Westhuyzen J
Ann Clin Lab Sci; 2000 Jul; 30(3):295-304. PubMed ID: 10945571
[TBL] [Abstract][Full Text] [Related]
33. Lipoperoxidation and hemodialysis.
Ramos R; Martínez-Castelao A
Metabolism; 2008 Oct; 57(10):1369-74. PubMed ID: 18803940
[TBL] [Abstract][Full Text] [Related]
34. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
35. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
[TBL] [Abstract][Full Text] [Related]
36. Plasma protein lipofuscin-like fluorophores in men with coronary artery disease treated with statins.
Sutherland WH; Williams MJ; de Jong SA
Arch Med Res; 2007 Oct; 38(7):757-63. PubMed ID: 17845895
[TBL] [Abstract][Full Text] [Related]
37. Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal failure patients on hemodialysis.
Samouilidou E; Karpouza A; Grapsa E; Tzanatou-Exarchou H
Nephron Clin Pract; 2010; 115(4):c289-94. PubMed ID: 20424480
[TBL] [Abstract][Full Text] [Related]
38. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
39. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
[TBL] [Abstract][Full Text] [Related]
40. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
